昭衍新藥(603127.SH)擬向通化中檢分析測試服務有限公司增資1000萬元
格隆匯11月18日丨昭衍新藥(603127.SH)公佈,基於戰略需求和業務拓展,公司與北京斯丹姆賽爾技術有限責任公司(下稱“斯丹姆”)與通化中檢分析測試服務有限公司(下稱“標的公司”)及其原股東隆裕弘達投資管理有限公司(下稱“隆裕弘達”)簽署《通化中檢分析測試服務有限公司投資協議》,公司與斯丹姆向標的公司各增資人民幣1000萬元,增資完成後標的公司的註冊資本由人民幣4300萬元增加至6300萬元,公司持有標的公司15.873%股權。
昭衍新藥通過投資通化中檢切入藥包材檢測業務,未來與通化中檢可拓展到生物血液樣品分析、臨牀一期項目分析及一致性評價等業務的合作,通化中檢的財務狀況會逐步好轉,長遠來看,有利於公司的發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.